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Red blood cell production is a finely tuned process
that requires coordinated oxygen- and iron-depen-
dent regulation of cell differentiation and iron metab-
olism. Here, we show that translational regulation
of hypoxia-inducible factor 2a (HIF-2a) synthesis
by iron regulatory protein 1 (IRP1) is critical for
controlling erythrocyte number. IRP1-null (Irp1/)
mice display a marked transient polycythemia.
HIF-2a messenger RNA (mRNA) is derepressed in
kidneys of Irp1/ mice but not in kidneys of Irp2/
mice, leading to increased renal erythropoietin (Epo)
mRNA and inappropriately elevated serum Epo
levels. Expression of the iron transport genes DCytb,
Dmt1, and ferroportin, as well as other HIF-2a
targets, is enhanced in Irp1/ duodenum. Analysis
of mRNA translation state in the liver revealed
IRP1-dependent dysregulation of HIF-2a mRNA
translation, whereas IRP2 deficiency derepressed
translation of all other known 50 iron response ele-
ment (IRE)-containing mRNAs expressed in the liver.
These results uncover separable physiological roles
of each IRP and identify IRP1 as a therapeutic target
for manipulating HIF-2a action in hematologic, onco-
logic, and other disorders.
INTRODUCTION
Erythropoiesis is a dynamic process regulated through the
complex interplay of cytokines, the availability of nutrients, and
the cellular environment of erythroid progenitors (Hattangadi
et al., 2011). The level of circulating erythrocytes must be tightly
controlled because a deficiency leads to anemia and that the
consequent negative impact of hypoxic stress, whereas chroni-
cally high levels can lead to hyperviscosity and potentially lethal282 Cell Metabolism 17, 282–290, February 5, 2013 ª2013 Elsevier Inthrombotic events (Lee and Percy, 2011). Excess accumulation
of erythrocytes, referred to as polycythemia or erythrocytosis,
occurs physiologically, as in an adjustment to high altitude, or
pathologically, because of intrinsic abnormalities in erythroid
precursors or as a consequence of inappropriately high expres-
sion of erythropoietin (Epo) (Lee and Percy, 2011). Critical factors
governing red cell formation include oxygen and iron sensing,
particularly through the transcription factor hypoxia-inducible
factor 2a (HIF-2a), which regulates Epo expression as well as
the expression of multiple other genes required for iron assimila-
tion (Gruber et al., 2007; Haase, 2010; Mastrogiannaki et al.,
2009; Scortegagna et al., 2005; Shah et al., 2009; Taylor et al.,
2011). Elucidating the mechanisms regulating Epo production
and action is relevant for understanding the etiology of, and to
design treatments for, common diseases and pathological
states ranging from the anemia of prematurity to the anemias
associated with inflammation, cancers, aging, and renal failure
(Strauss, 2010; Weiss and Goodnough, 2005).
HIFs are heterodimeric transcription factors regulated by
oxygen and iron (Majmundar et al., 2010; Prabhakar and
Semenza, 2012). HIFs contain a subunit from a family of inducibly
degraded a proteins that have overlapping but unique physiolog-
ical and pathophysiological roles. The key role of HIF-2a in eryth-
ropoiesis has been demonstrated, in part, through the discovery
of human HIF-2a gain-of-function mutations that cause polycy-
themia (Lee and Percy, 2011). Dysregulation of HIF-2a is also
implicated in human cancers (Franovic et al., 2009; Keith et al.,
2012; Tong et al., 2011). Although much previous work has
focused on the regulation of HIF action through oxygen- and
iron-mediated protein degradation, recent work with cultured
cells has revealed new mechanisms for HIF regulation, including
programmed changes in their synthesis (Sanchez et al., 2007;
Tong et al., 2011; Young et al., 2008; Zimmer et al., 2010).
Thus, physiological control of HIF-2a function and its dysregula-
tion in disease may arise because of adaptive or maladaptive
changes in HIF-2a synthesis.
Iron regulatory protein 1 (IRP1) and IRP2 are central regulators
of cellular iron metabolism in metazoans (Anderson et al., 2012;
Hentze et al., 2010). IRPs control the fate of messenger RNAsc.
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metabolism or the adaptive responses to iron deficiency. The
finding that a deficiency of IRP2, but apparently not of IRP1,
leads to dysregulated iron metabolism (Cooperman et al.,
2005; Galy et al., 2005b; Meyron-Holtz et al., 2004) has led to
the view that IRP1 lacks a unique role in iron metabolism.
However, the fact that the Fe-S switch mechanism controlling
IRP1 allows for the inactivation of its RNA binding in hypoxia,
in contrast to IRP2, which is activated, suggests otherwise
(Anderson et al., 2012). Thus, as is the case for HIF-2a mRNA
in cultured cells, translation of mRNAs preferentially repressed
by IRP1 would be enhanced in hypoxia (Zimmer et al., 2008).
These findings suggest that an IRP1-HIF-2a regulatory axis
may be a critical component of systemicmechanisms controlling
erythrocyte number as well as tissue responses to iron defi-
ciency and hypoxic stress.
Here, we studied the impact of IRP1 deficiency on the function
of HIF-2a in erythropoiesis and duodenal iron absorption. Our
study reveals that, through its regulation of HIF-2a expression,
IRP1 has a key role linking erythropoiesis and dietary iron
absorption with iron and oxygen sensing, a function not attrib-
uted to IRP2. The IRP1-HIF-2a axis provides new therapeutic
targets for modulating the response of cells to altered iron or
oxygen levels in a wide array of hematologic and oncologic
diseases.
RESULTS
Polycythemia and Extramedullary Erythropoiesis
in IRP1-Deficient Mice
In the process of elucidating the unique physiological functions
of IRP1 and IRP2, we observed that young IRP1-null (Irp1/)
mice frequently had reddened paws around 5 weeks of age (Fig-
ure 1A), reminiscent of the ‘‘plethora’’ seen in human patients
with polycythemias. Accordingly, we found that hematocrit, red
cell number, and hemoglobin are elevated in Irp1/ mice
between 4 and 6weeks of age (Figure 1B, and Table S1 available
online). The elevated hematocrit level is similar to that observed
in humans with HIF-2a gain-of-function mutations (Lee and
Percy, 2011). Irp1/ spleens aremost enlarged at 4 and 5weeks
of age but thereafter normalize (Figures 1C and 1D). Serum and
tissue iron parameters are indicative of iron redistribution to
the erythron (Table S2). When Irp1/ mice reach 8 weeks of
age, the hematocrit remains elevated although there is substan-
tial variability from animal to animal such that only approximately
one-third of the animals have elevated hematocrit. At this age,
the hematocrit of Irp1/ and Irp1+/+ is not statistically different
(p = 0.058), illustrating the age-dependent effect of IRP1 defi-
ciency (Figure 1B).
Spleens from 5-week-old Irp1/ mice demonstrated an
altered architecture, characterized by a decreased white pulp
and a substantially increased red pulp, signifying expanded
erythropoiesis (Figure 1E). Immunohistochemistry for TfR1
(CD71) confirmed that the Irp1/ splenic red pulp is distended
by erythroblasts (Figure 1E). Maturing erythroblasts of different
developmental stages were quantified by flow cytometry with
the erythroid-specificmarker Ter119 andwith CD71 (Socolovsky
et al., 2001). This analysis reveals the marked accumulation
of erythroblasts in bone marrow and particularly in spleens ofCell M5-week-old Irp1/mice (Figures 1F and 1G). The relative abun-
dance of cells at different stages of erythroblast maturation was
not altered in bone marrow (BM), whereas, in the Irp1/ spleen,
the distribution was skewed toward having more cells at stage II
and fewer cells at stage IV (Figure 1H and Table S3). This altered
pattern of maturation may reflect the response to Epo itself or to
changes induced by the splenic microenvironment (Socolovsky
et al., 2001). Interestingly, at 6 weeks of age, enhanced erythro-
poiesis was only observed in about one-quarter of the Irp1/
mice, indicating an age-dependent compensation for the loss
of IRP1 (Figures S1C and S1D).
To determine whether IRP1 deficiency caused a specific
enhancement of erythropoiesis, the abundance of hematopoi-
etic progenitors was determined. IRP1 deficiency does not
appear to affect the abundance of primitive hematopoietic
stem and progenitor cells (LinSca1+c-kit [LSK] cells) or
myeloid progenitor cells in either the BM or the spleen (SP) (Fig-
ure 2A). Consistent with the flow cytometric analysis, early-stage
myeloid progenitors formed similar numbers of colonies in vitro,
irrespective of genotype (Figure 2B). In contrast, the primitive
erythroid BFU-E and late-stage CFU-E progenitors were
elevated in BM and particularly in SP of Irp1/ mice, whereas
progenitors for other hematopoietic lineages were not altered
(Figures 2B and 2C). Then, we determined whether IRP1 defi-
ciency affected the sensitivity of CFU-E cells to Epo. No such
effect was observed (Figure 2D). Collectively, these findings
reveal that IRP1 deficiency is associated with an age-dependent
increase in erythropoiesis in young mice and not a general
increase in hematopoiesis. We conclude that IRP1 has a previ-
ously unrecognized role as a regulator of erythropoiesis and
that its dysregulation contributes to the development of polycy-
themia. The erythroid phenotype of IRP1 is distinct from that of
IRP2 deficiency—e.g., microcytic anemia and erythropoietic
protoporphyria (Cooperman et al., 2005; Galy et al., 2005b).
Enhanced Serum Epo and Erythroid Gene Expression
in Spleen of Irp1–/– Mice
Given that HIF-2a is a major regulator of Epo gene transcription
and that HIF-2amRNA translation is a direct target of IRP action
(Davis et al., 2011; Sanchez et al., 2007; Zimmer et al., 2008), Epo
expression was examined in Irp1/ mice. Epo expression is
developmentally regulated after birth, reflecting the increased
oxygen level relative to in utero levels, an increased demand
for erythropoiesis, and a relative iron deficiency as the neonate
grows (Lee and Percy, 2011). The maximal changes observed
in erythropoiesis in Irp1/mice relative to Irp1+/+ mice occurred
at 5 weeks of age, which was coincident with the slowing of
growth and the attendant increase in red blood cell mass as
the animal reaches adult weight. To determine whether the effect
was Epo-dependent, we measured serum Epo concentration in
4-, 5-, and 8-week-old mice. At 4 weeks, serum Epo concentra-
tion was high in Irp1+/+ and Irp1/ mice, most likely reflecting
a physiologically appropriate erythropoietic drive in young mice
(Figure 3A). However, at 5 weeks, when the difference in erythro-
poiesis is apparent in Irp1/mice, serumEpo level is 2- to 3-fold
higher than in Irp1+/+ mice. At this time, kidney Epo mRNA is
increased by more than 8-fold in Irp1/ animals (Figure 3B).
Furthermore, expression of multiple genes involved in erythroid
development, including globins and heme biosynthetic genes,etabolism 17, 282–290, February 5, 2013 ª2013 Elsevier Inc. 283
Figure 1. Polycythemia and Extramedullary Erythropoiesis in IRP1-Deficient Mice
(A) Rear paws showing greater redness in Irp1/ mice.
(B) Hematocrit analysis for Irp1+/+ and Irp1/ mice. Samples were collected from the retroorbital sinus or by cardiac puncture and hematocrit was from CBC
analysis. n = 2 for 30-week Irp1+/+ mice.
See also Table S1.
(C) Spleens from 6-week-old wild-type (WT) and Irp1/ mice.
(D) Spleen weight as a percent body weight as a function of age. n = 2 for 30-week Irp1+/+ mice.
(E) Hematoxylin and eosin (H&E) staining (top) or immunohistochemistry for CD71(TfR1) (bottom) in spleens.
(F) Fluorescence-activated cell sorting (FACS) analysis of cells isolated from bone marrow (BM) and spleen (SP) with staining for the erythroid marker Ter119
and CD71 (TfR). The cell populations are separated into stage I –stage IV reflecting increasing differentiation of the erythroblasts as described (Socolovsky
et al., 2001).
(G) Percentage of nucleated cells that are erythroblasts in BM and SP.
(H) Erythroblast differentiation state in BM and SP as determined by FACS. For panels (B), (D), (G), and (H), results are expressed as mean ± SEM. *, p < 0.05; **,
p < 0.01; ***, p < 0.001. Unless noted, 5-week-old mice were used.
See also Tables S1, S3, and Figure S1.
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increased erythroblast number. Given that Epo promotes the
expansion of BFU-E and CFU-E cells (Peslak et al., 2012), the
rise in these erythroid progenitors in Irp1/ mice at 5 weeks of
age can be explained by an inability to suppress Epo expression.
Interestingly, serum Epo concentration at 8 weeks of age is
persistently high in Irp1/ mice. Given that erythropoiesis re-
turns to normal by about 6 weeks in Irp1/ mice (Figures S1C
and S1D), it appears that erythroid differentiation has become284 Cell Metabolism 17, 282–290, February 5, 2013 ª2013 Elsevier Indesensitized to the elevated Epo. Epo resistance is clinically
relevant in a number of chronic disease states and can be
causedby iron deficiency, inflammatory cytokines, or a reduction
of Epo-responsive, late-stage erythroid progenitors (Andrews
and Bridges, 1998; Peslak et al., 2012; van der Putten et al.,
2008). Because the reduction in transferrin iron in Irp1/ mice
(Table S2) does not appear to reach a level that impairs erythro-
poiesis, at least in vitro (Bullock et al., 2010), we conclude that
other factors are most likely responsible. In summary, wec.
Figure 2. Specific Increase in Erythroid
Progenitors in Irp1–/– Mice
(A) Abundance of myeloid progenitor cells (LSK,
LinSca1+c-kit; MP, myeloid progenitors; CMP,
common myeloid progenitors; GMP, granulocyte
macrophage progenitors; MEP, megakaryocyte
erythroid progenitors) in SP and BM. For panels
(B), (C) and (D), BM andSP cells were isolated from
Irp1+/+ and Irp1/ mice and plated in duplicate in
M3234 medium with 3 U/ml ([B] and [C]) or varying
concentrations ([D]) of Epo.
(B) Average percentage of the maximum number
of colonies formed in culture. For BFU-E (burst
forming unit-erythroid), CFU-G (colony forming
unit [CFU]-granulocyte), CFU-M (CFU-macro-
phage),CFU-GM(CFU-granulocyte-macrophage),
and CFU-GEMM (CFU-granulocyte, erythroid,
macrophage, megakaryocytic) colony formation,
BM, and SP cells were plated in anM3434medium
and colonies were counted at day 7 after plating.
(C) CFU-E (CFU-erythroid) number in BM and SP
cells.
(D) CFU-E number as a function of Epo concen-
tration. Error bars show SEM. *, p < 0.05; **,
p < 0.01; ***, p < 0.001. Mice were 5 weeks old.
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mental signal that normally acts through IRP1 to suppress HIF-
2a synthesis is absent, leading to a failure to suppress Epo
expression. As Irp1/mice age, one of many factors controlling
Epo action or other aspects of erythropoiesis acts to limit red cell
production because of IRP1 deficiency and compensates for the
inappropriately high Epo level.
HIF-2a Hyperactivity in Duodenum of Irp1–/– Mice
HIF-2a induces transcription of the duodenal iron transporter
genes in response to hypoxia or iron deficiency (Taylor et al.,
2011). The mRNAs that encode key components of the apical
(DCytb [Cybrd1] and Dmt1 [Slc11a2]) and basolateral (ferro-
portin [Slc40a1]) iron transporters are significantly increased
in Irp1/ duodenal mucosal cells (Figure 3D). The preferential
impact of IRP1 deficiency on the iron response element
(IRE)-containing forms of DMT1 mRNA is consistent with thisCell Metabolism 17, 282–290isoform being a target of HIF-2a action
(Mastrogiannaki et al., 2009; Shah
et al., 2009).
Using a transcriptomic approach, we
found 25 genes that were differentially
expressed between Irp1+/+ and Irp1/
duodenum (Figures 3E and S2). Among
these genes are DCytb (Cybrd1) and
Dmt1 (Slc11a2). Multiple other molecular
signatures emerged as well. First, ex-
pression of the prolyl hydroxylase Egln3
mRNA (Phd3 mRNA) that controls HIFa
protein stability is increased in Irp1/
duodenum (Figures 3D, 3E, and S2).
EGLN3 is part of a feedback loop for
HIF-2a, and the Egln3 gene contains
a bona fide hypoxia response element(Lee and Percy, 2011; Minamishima et al., 2009; Pescador
et al., 2005). Second, induction of the amino acid transporter
SLC38A1 and the enzyme gamma-glutamyl hydrolase (GGH)
by iron deficiency requires HIF-2a (Taylor et al., 2011). Duodenal
expression of both genes is increased in Irp1/ mice (Figures
3D and 3E). Third, in addition to DCytb, Dmt1, ferroportin
(Slc40a1), Slc38a1, Ggh and Egln3, the expression of Pparg,
Nt5E, and Snca mRNAs are also altered in Irp1/ duodenum
(Figures 3E and S2). Each of these genes is either an HIF-2a
target or responsive to the O2 level (see Figure S2). Altogether,
the polycythemia observed in Irp1/ mice is linked with
increases in HIF-2a activity and, as such, supports the notion
that a loss of IRP1 is similar to an HIF-2a gain of function.
On this basis, we conclude that IRP1 provides a critical link
between the fundamental pathways of cellular iron and oxygen
use and the systemic regulation of iron absorption and
erythropoiesis., February 5, 2013 ª2013 Elsevier Inc. 285
Figure 3. HIF-2a Hyperactivity in IRP1-Deficient Mice
(A) Serum Epo (pg/ml) in 4-, 5-, and 8-week-old mice.
(B) Kidney Epo messenger RNA (mRNA) level at 5 weeks.
(C) Erythroid differentiation gene mRNA levels in the spleen at 5 weeks.
(D) Duodenal mRNA level for iron transport proteins and other hypoxia-inducible factor 2a (HIF-2a) (e.g., EGLN3) targets dependent on HIF-2a for induction in iron
deficiency (5 weeks).
(E) Microarray analysis of duodenal mucosal cells at 5 weeks. Response of each of four mice per genotype is shown. Posterior probability of differential
expression for all genes is <0.95. Expression of five erythroid genes (globin chains a1, a2, b1, b2, and ALAS2) is not shown. Results in this figure are expressed as
mean ± SEM. *, p < 0.05; **, p < 0.01; ***, p < 0.001.
See also Supplemental Experimental Procedures and Figure S2.
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in Irp1–/– Mice
To determine the basis for the development of polycythemia in
Irp1/ but not Irp2/mice, we determined the translation state
of HIF-2a and other 50 IRE-containing mRNAs (Figure 4 and
Tables S4 and S5). Repressed mRNA in ribonucleoprotein parti-
cles (RNP) are separated from the 80S monosomes and the
translationally active polysomes by polysome profile analysis.
Given the increased expression of EpomRNA in Irp1/ kidneys,
we asked whether the HIF-2a mRNA translation state was
altered. In Irp1+/+ kidneys, nearly equal amounts of HIF-2a
mRNA were in the RNP and polysome bound pools (Figure 4A).
Strikingly, in Irp1/ but not Irp2/ mouse kidneys, HIF-2a
mRNA was substantially derepressed such that the majority
was polysome-bound in comparison to those of Irp1+/+ mice.
Thus, IRP2 does not compensate for the absence of IRP1 in
maintaining the wild-type level of repression of HIF-2a mRNA
translation. Deficiency of either IRP failed to affect b-actin
mRNA translation (Figure 4A). Thus, the polycythemia in Irp1/
mice is associated with a selective translational derepression of
HIF-2a mRNA in kidneys not seen in Irp2/ mice.
Then, we investigated the role that each IRP had in controlling
the translation state of 50 IRE-containing mRNAs in the liver,
a tissue in which HIF-2a has many metabolic roles (Haase,286 Cell Metabolism 17, 282–290, February 5, 2013 ª2013 Elsevier In2010). The liver expresses less IRP1-RNA binding activity in
comparison to kidneys (Meyron-Holtz et al., 2004). Thus, it was
not surprising that a larger fraction of HIF-2a mRNA was poly-
some-bound in comparison to kidneys (Figure 4B and Table
S5). Similar to kidneys, loss of IRP1, but not IRP2, led to transla-
tional derepression of HIF-2a mRNA. However, all other 50
IRE-containing mRNAs in the liver showed the opposite result.
Translational derepression of H- and L-ferritin, ferroportin, and
mitochondrial aconitase mRNAs was observed in Irp2/ but
not in Irp1/ livers (Figure 4B and Table S5). Altogether, our
findings illustrate unique roles for each IRP in orchestrating the
fate of 50 IRE-containing mRNAs.
Next, we asked whether the selective dysregulation of HIF-2a
in Irp1/mice related to the level or selectivity of IRP1 and IRP2
binding activity in kidneys. Previous studies in 786-O cells found
that the level of IRP2 expressed was insufficient to bind to the
HIF-2a IRE (Zimmer et al., 2008). Kidney cytosol extracts from
Irp1/ or Irp2/mice were the source of IRP2 or IRP1, respec-
tively, in electrophoretic mobility shift assays (Figure 4C). HIF-2a
IRE binds to IRP1 as well or better than the L-ferritin IRE (Fig-
ure 4C, subpanels 1 and 2). Consistent with previous studies,
IRP2 binding activity wasmuch lower than that of IRP1 in kidneys
(Meyron-Holtz et al., 2004). However, in contrast to IRP1, IRP2
bound to the L-ferritin IRE better than it did to the HIF-2a IRE.c.
Figure 4. Selective Dysregulation of HIF-2a mRNA Translation in Irp1–/– Mice
(A) Kidney polysome profile (PP) analysis at 8 weeks. A typical PP is shown.
(B) Liver PP analysis at 8 weeks.
(C) Electrophoretic mobility shift assays from Irp2/ or Irp1/ kidney cytosol. Panels (1) and (2) show binding of RNAs (0.5 nM) with the use of Irp2/ kidney
cytosol, therefore binding is to IRP1. Panels (3) and (4) show binding of RNAs (0.5 nM) with the use of Irp1/ kidney cytosol, therefore binding is to IRP2. Result is
representative of n = 2 experiments. A proposed secondary structure of L-ferritin and HIF-2a IRE is also shown.
(D) Model of the impact of IRP1 on HIF-2a regulation. Results in panels (A) and (B) are expressed as mean ± SEM. *, p < 0.05; **, p < 0.01; ***, p < 0.001.
See also Tables S4 and S5.
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is associated with a reduced level of IRP2-RNA binding activity
in kidneys in comparison to IRP1 coupled with a greater prefer-
ence of IRP2 for the L-ferritin IRE.
Our study adds an important component to the existing para-
digms concerning the integrated regulation of iron and oxygen
metabolism in mammals. First, the polycythemic phenotype of
Irp1/mice illustrates that control of HIF-2a synthesis is amajor
aspect of IRP1 function. A key consequence of this is that IRP1
will amplify the impact of prolyl hydroxylase-mediated regulation
of HIF-2a accumulation in response to oxygen while dampening
the action of iron (Figure 4D). Given that the Irp1/ mice used
here were fed a normal diet under normoxic conditions, altered
exposure to iron or oxygenwill most likely exacerbate the pheno-
type of IRP1 deficiency. Second, IRP1 has a physiologic role
separable from IRP2 that suggests that IREs can be functionally
distinct in vivo. The presence of a similar noncanonical 30
unpaired nucleotide in the DMT1 IRE, as is predicted for
HIF-2a (Figure 4C), and its preferential recognition by IRP1
suggest a mechanism for IRP selectivity (Gunshin et al., 2001).
Third, the key role of the Fe-S switch in controlling IRP1 RNA
binding activity predicts unanticipated links betweenmajor path-
ways of iron metabolism (e.g., Fe-S cluster biogenesis), HIF-2a,
and oxygen sensing that when perturbed may contribute to
disease phenotypes. Fourth, the finding that the oxygen sensi-
tivity of the Fe-S switch mechanism of IRP1 may be modulated
by S138 phosphorylation suggests critical mechanisms that
may contribute to pathological abnormalities in Epo expression
or other aspects of HIF-2a action (Andrews and Bridges, 1998;
Deck et al., 2009; van der Putten et al., 2008).
The sensing of oxygen and iron is a central aspect of the
homeostatic responses in a wide spectrum of physiological
scenarios and its dysregulation is a pathophysiological feature
of diseases, including polycythemias and other erythropoietic
diseases, pulmonary syndromes, renal disease, cancers, and
other disorders (Prabhakar and Semenza, 2012). Although
HIF-2a and IRP1 respond to hypoxia, iron deficiency, and other
metabolic stresses, the extent to which they do so in a concerted
manner has only recently come into greater focus (Taylor et al.,
2011; Zimmer et al., 2010). The current demonstration that
IRP1 is the key IRP regulator of HIF-2a establishes a broad
framework through which the regulation of iron and oxygen
homeostasis is integrated and provides an important paradigm
for defining how maladaptive regulation of this network contrib-
utes to human diseases.
EXPERIMENTAL PROCEDURES
Mice
The generation of tissue-wide Irp1/ and Irp2 / mice has been described
previously (Galy et al., 2005a). Irp1/ and Irp2/ mice used here were back-
crossed six generations with C57BL/6 mice. Irp1+/ or Irp2+/ mice were bred
to generate Irp1/ and Irp2/ mice and their wild-type littermates. Animal
use met the requirements of the University of Wisconsin-Madison Institutional
Animal Care and Use Committee.
Hematologic and Iron Parameters
Blood was drawn from the retroorbital sinuses or hearts for complete blood
count (CBC) analysis, for calculated or manual hematocrit analysis, or for
serum for the Epo quantikine ELISA kit (MEP00B; R&D Systems). For CBC
and hematocrit analyses, blood was collected into heparin- or EDTA-treated288 Cell Metabolism 17, 282–290, February 5, 2013 ª2013 Elsevier Intubes. CBC analysis was performed at the University of Wisconsin-Madison
School of Vetrinary Medicine. Blood and tissue were analyzed for serum iron
or tissue nonheme iron as described previously (Schmidt et al., 2010).
Flow Cytometry
For hematopoietic cell lineage analysis, flow cytometric analyses were per-
formed as described previously (Socolovsky et al., 2001; Zhang et al., 2009).
LSK cells and myeloid progenitors were also determined by flow cytometry
(Wang et al., 2011). Stained cells were analyzed on a FACSCalibur flow cytom-
eter (BD Biosciences) or on a MACS Quant Analyzer (Miltenyi Biotec). Colony-
forming assays for the quantization of BFU-E and various CFU progenitors and
Epo sensitivity of CFU-E used growth in methylcellulose with defined media
(STEMCELL Technologies). The antibodies directed against cell-surface anti-
gens and other details of the flow cytometry procedure are described in the
Supplemental Experimental Procedures.
Tissue Staining and Immunohistochemistry
Spleenswere fixed in 10%buffered formalin and embedded in paraffin. Depar-
affinized sections of tissue were stained with hematoxylin and eosin or CD71
antibody (TfR1) at the Children’s Hospital Boston Department of Pathology
Histology Lab. Images were acquired with the use of a 43/0.13 objective
lens on a BX51 microscope with a DP71 Digital Camera with the use of
Olympus MicroSuite FIVE Imaging Software.
PCR Analysis
RNA was isolated with the use of RNA STAT-60 (Tel-Test). Reverse-transcrip-
tion used total RNA, Superscript III (Invitrogen), and random hexamers. Real-
time PCR on complementary DNA used SYBRGreen PCRMasterMix (Applied
Biosystems) on an ABI 7000.
Polysome Profile Analysis
Tissues were minced and homogenized in 3 volumes of polysome buffer (PB)
(40 mM HEPES [pH 7.4], 100 mM Cl, 5 mM MgCl2, 2 mM citrate, and 1 mM
DTT) in a Potter-Elvehjem homogenizer. The homogenate was centrifuged at
5000 3 g at 4C for 20 min. The upper two-thirds of the supernatant was
brought to 1% Na deoxycholate, 1% Triton X-100 in PB. A 500 ml sample
was loaded on a linear 15%-to-60% sucrose gradient in PB and centrifuged
at 180,000 3 g in a Sorvall TH641 rotor for 2 hr at 4C. Gradient fractionation
used an ISCO UA-6 and 254 nm detector linked to an Agilent integrator.
Electrophoretic Mobility Shift Assays
An RNA binding assay with [32P] IREs (15,000 dpm 15,000 dpm/fmol) was
performed as described previously (Goforth et al., 2010).
Microarray
Mice were fasted overnight and killed under isoflurane. Total RNAwas isolated
from frozen duodenal mucosal cells (see PCR Analysis), labeled with the use of
the Ambion Gene ChipWT Expression Kit (Ambion), and hybridized to Affyme-
trix Mouse Gene 1.0 ST Arrays.
Statistical Methods
Groupmeanswere tested for differences by Student’s t tests. Error bars repre-
sent SEM. Statistical analysis of arrays is described in the Supplemental
Experimental Procedures.
SUPPLEMENTAL INFORMATION
Supplemental Information contains Supplemental Experimental Procedures,
two figures, and six tables and can be found with this article online at http://
dx.doi.org/10.1016/j.cmet.2013.01.007.
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